Trial reportAnnals of the rheumatic diseases2007
A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone.
Trial report in Annals of the rheumatic diseases, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Immunosuppressive treatment for proliferative lupus nephritis.The Cochrane database of systematic reviews · 2018Pooled it
- Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.Annals of the rheumatic diseases · 2012Guideline
- Salmonella infection and biofilms drive anti-C1q and anti-dsDNA autoantibodies in systemic autoimmunity.PLoS pathogens · 2026Article
- Lupus Nephritis Biomarkers: A Critical Review.International journal of molecular sciences · 2024Review
- Biomarkers Associated with Drugs for the Treatment of Lupus Nephritis.Biomolecules · 2023Review
- Lupus Nephritis Risk Factors and Biomarkers: An Update.International journal of molecular sciences · 2023Review
- A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE.Rheumatology (Oxford, England) · 2020Article
- Anti-DNA antibodies--quintessential biomarkers of SLE.Nature reviews. Rheumatology · 2016Review
- Autoantibodies against Modified Histone Peptides in SLE Patients Are Associated with Disease Activity and Lupus Nephritis.PloS one · 2016Article
- PTX3, Anti-PTX3, and Anti-C1q Autoantibodies in Lupus Glomerulonephritis.Clinical reviews in allergy & immunology · 2015Article
- Article
- The value of a panel of autoantibodies for predicting the activity of lupus nephritis at time of renal biopsy.Journal of immunology research · 2015Article
- Novel Autoantigens Associated with Lupus Nephritis.PloS one · 2015Article
- The spectrum of anti-chromatin/nucleosome autoantibodies: independent and interdependent biomarkers of disease.Journal of immunology research · 2014Review
- Biomarkers in systemic lupus erythematosus: challenges and prospects for the future.Therapeutic advances in musculoskeletal disease · 2013Article
- Anti-C1q autoantibodies, novel tests, and clinical consequences.Frontiers in immunology · 2013Article
- Autoantibodies and resident renal cells in the pathogenesis of lupus nephritis: getting to know the unknown.Clinical & developmental immunology · 2012Review
- Biomarkers for lupus nephritis: a critical appraisal.Journal of biomedicine & biotechnology · 2010Review
- Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study.Arthritis research & therapy · 2009Article
- Anti-C1q antibodies: association with nephritis and disease activity in systemic lupus erythematosus.Journal of clinical laboratory analysis · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo study the prevalence and course of anti-chromatin (anti-nucleosome, anti-double-stranded (ds) DNA and anti-histone) and anti-C1q autoantibodies in patients with proliferative lupus nephritis (LN), treated in a randomised controlled trial with either cyclophosphamide or azathioprine plus methylprednisolone.
methodsAutoantibody levels were measured and analysed in 52 patients with proliferative LN, during their first year of treatment. Levels in both treatment arms were compared and associations with clinical, serological and outcome parameters were studied.
resultsAt study entry, prevalences for anti-nucleosome, anti-dsDNA, anti-histone and anti-C1q autoantibodies were 81%, 96%, 23% and 65%, respectively. Anti-chromatin autoantibodies correlated with each other, but not with anti-C1q levels. If patients were divided for their autoantibody titre at the start of treatment above or below the median, the only significant differences were higher SLE disease activity index with higher anti-nucleosome, and higher creatinine with higher anti-C1q autoantibodies. During the first year, a comparable rapid decline in the levels of anti-nucleosome, anti-dsDNA and anti-C1q autoantibodies was seen in both treatment arms. Anti-histone autoantibody levels were low and did not change. Renal flares were not preceded by rises in autoantibody titres.
conclusionsThese results indicate that measurement of anti-chromatin and anti-C1q autoantibodies is useful for diagnosing LN, but not for monitoring disease course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.